UPDATED May 15, 2024
Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
1373 | HK$1.31 | -1.5% | -54.7% | HK$943.1m | n/a | PE7.7x | n/a | 8.5% | Retail | ||
1086 | HK$0.63 | -4.5% | 5.0% | HK$1.1b | n/a | PE5.2x | E21.8% | 0% | Consumer Durables | ||
81 | HK$2.03 | 14.0% | -50.7% | HK$7.2b | HK$2.51 | PE2.9x | E-2.4% | 7.9% | Real Estate Management and Development | ||
35 | HK$1.17 | 11.4% | -40.6% | HK$3.3b | HK$2.00 | PB0.2x | E137.4% | 12.0% | Real Estate Management and Development | ||
1765 | HK$0.28 | 15.1% | -52.6% | HK$2.3b | n/a | PE376.3x | E53.9% | n/a | Consumer Services | ||
302 | HK$1.32 | -1.5% | -42.6% | HK$3.6b | HK$2.53 | PS1.3x | E22.1% | n/a | Media | ||
1600 | HK$4.60 | -3.0% | -22.3% | HK$4.5b | HK$5.16 | PE8.6x | E13.1% | 4.1% | Utilities | ||
2256 | HK$3.70 | 5.7% | 36.5% | HK$2.4b | HK$8.20 | PS116.3x | E-2.3% | n/a | Pharmaceuticals & Biotech | ||
2120 | HK$11.86 | 5.0% | n/a | HK$872.4m | n/a | PE9.4x | n/a | 3.6% | Healthcare | ||
842 | HK$1.50 | 2.7% | 18.1% | HK$2.1b | n/a | PE3.5x | n/a | 9.3% | Capital Goods | ||
520 | HK$2.24 | 23.8% | -54.3% | HK$2.4b | HK$2.17 | PB1.9x | E55.3% | 2.7% | Consumer Services | ||
1426 | HK$2.00 | 0% | -14.9% | HK$2.9b | n/a | PB0.4x | n/a | 9.0% | Real Estate | ||
2342 | HK$0.68 | 7.9% | -53.4% | HK$1.9b | n/a | PE279x | n/a | 0% | Tech | ||
9919 | HK$1.28 | -0.8% | -3.8% | HK$953.3m | HK$2.29 | PE8.2x | S14.1% | 13.1% | Media |